LAKEWOOD, Colo. - Thursday, March 21st 2013
Terumo BCT has acquired Medservice, a leading distributor of medical products and services to blood banks and hospitals in Poland.
Medservice has been a Terumo BCT distributor to blood banks in Poland since 2006. The acquisition provides Terumo BCT a direct relationship with Polish blood banks, to drive the further adoption of critical blood transfusion technologies that can improve the safety and quality of blood in Poland.
Key Facts:
Medservice, with its headquarters in Katowice, Poland and a branch office in Warsaw, has been in business for 24 years
Medservice has been a Terumo BCT distributor to blood banks in Poland since 2006
Medservice’s main business segment is blood banks in Poland
Medservice also distributes therapeutic apheresis products to hospitals
Key Quotes:
Vincent Gaspar, Senior Vice President and General Manager EMEA, Terumo BCT
“The acquisition of Medservice underscores our global commitment to deliver technology that provides safer blood and improves the quality of blood components and further strengthens our global offerings. We plan to build on Medservice’s strong reputation for customer service, quality and collaboration, and provide customers with a broader portfolio of products and services.”
Vincent Gaspar, Senior Vice President and General Manager EMEA, Terumo BCT
“Strategically Medservice is a great fit. It is a well-run company with a strong reputation for customer service, quality and collaboration. With this acquisition we will build on our strong presence in Poland and the success we have had with our blood safety and automation initiatives. We look forward to supporting our customers with additional field-based resources and in providing them with direct access to our wide range of products and services.”
About Medservice:
Medservice is a Poland-based company providing high-quality medical products and services to domestic and foreign customers. Its mission is to gain and maintain customers’ trust and satisfaction by supplying quality products that are safe and compliant with the latest findings in the field of medicine.
About Terumo BCT:
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.
Principal Terms and Closing:
The transaction has been structured as a share purchase and is expected to close in Terumo BCT’s fourth fiscal quarter, subject to approval and customary conditions. After the closing, Medservice will be operated as a subsidiary of Terumo BCT Europe, N.V.
Special Note:
Statements that relate to future results and events are forward-looking statements based on Terumo BCT’s and Medservice’s current expectations. Actual results and events in future periods may differ materially from those expressed or implied by these forward-looking statements because of a number of risks, uncertainties and other factors. Risks, uncertainties and assumptions include the possibility that projected benefits may not materialize as expected; that the transaction may not be timely completed, if at all; that Terumo BCT and Medservice are unable to successfully implement the plans, strategies and objectives of management for future operations.
Contacts
Terumo BCT
D. Nikki Wheeler, +1-303-205-2828
Global Corporate Communications
press@terumobct.com
No comments:
Post a Comment